Maintenance Outage Our services will be offline from Friday, May 22 to Monday, May 25th, for routine maintenance. We apologize for any inconvenience this may cause you. Due to extended maintenance services will remain offline through Thursday, May 28, 2026.

Back to Resources

AstraZeneca and Daiichi Sankyo Tout Enhertu Approval Status Updates in Q1 2026

April 1, 2026

Market Highlights

AstraZeneca and Daiichi Sankyo announced that Enhertu was granted Priority Review status.
Materials touted the drug’s availability in Japan for HER2-positive metastatic gastric cancer.
Readers were informed about the brand’s approval in Japan for HER2-positive solid tumors.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com